Table 4.

Relationships between ECG abnormalities and chemotherapy regimens

Chemotherapy regimen	Total (cases)	ST-T segment abnormalities			Elevated myocardial enzymes			Arrhythmia			QRS pattern or duration abnormalities
		No. of events [cases (%)]	χ2	P value	No. of events [cases (%)]	χ2	P value	No. of events [cases (%)]	χ2	P value	No. of events [cases (%)]	χ2	P value
Anthracycline-based	22	12 (54.5)	6.977	0.008	0 (0)	0.020	0.889	4 (18.2)	2.519	0.112	4 (18.2)	1.224	0.269
Taxane-based	56	13 (23.2)	2.331	0.127	1 (1.8)	0.001	0.980	21 (37.5)	0.179	0.672	2 (3.6)	2.687	0.001
Anthracycline–taxane-based	66	19 (28.8)	0.188	0.665	3 (4.5)	0.515	0.430	25 (37.9)	0.329	0.566	8 (12.1)	0.938	0.333
Others	3	1 (33.3)	0.000	1.000	0	0.000	1.000	2 (66.7)	0.287	0.592	0	0.000	1.000